Epidemiological characteristics of toxoplasmic encephalitis in 399 HIV- infected patients followed from 1983 to 1994;Caracteristiques epidemiologiques des toxoplasmoses cerebrales chez 399 patients infectes par le VIH suivis entre 1983 et 1994

Revue de Medecine Interne

Volumn 19, Issue 5, 1998, Pages 313-317

  Bossi, P ^a   Caumes, E ^a   Astagneau, P ^a   Li, T S ^a   Paris, L ^a   Mengual, X ^a   Katlama, C ^a   Bricaire, F ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AIDS; Epidemiology; HIV; Toxoplasmic encephalitis

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; PENTAMIDINE; PROTOZOON ANTIBODY; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; COCCIDIOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ENCEPHALITIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RELAPSE; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT FAILURE; AIDS RELATED COMPLEX; ANIMAL; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; COMPUTER ASSISTED TOMOGRAPHY; DATA BASE; FOLLOW UP; FRANCE; IMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; SURVIVAL RATE; TIME; TOXOPLASMA; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES, PROTOZOAN; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHEMOPREVENTION; COCCIDIOSTATS; DATABASES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HIV INFECTIONS; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; PENTAMIDINE; PNEUMONIA, PNEUMOCYSTIS; RECURRENCE; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL; TREATMENT FAILURE; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0032062798     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(98)80100-8     Document Type: Article

References (31)

1. 1 Luft BJ, Remington JS. Toxoplamic encephalitis in AIDS. Clin Infect Dis 1992 ; 15 : 211-6
2. 2 Mc Arthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore) 1987 ; 66 : 407-37
3. 3 Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994 ; 121 : 769-85
4. 4 Luft BJ, Remington JS. Toxoplasmosis of the central nervous system. In: Remington JS, Swartz MN. eds. Current clinical topics in infectious diseases. Vol 6. New York: Mc Graw-Hill; 1985. p 315-58
5. 5 Levy RM, Bredesen DE. Central nervous system dysfunction in acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988 ; 1 : 41-52
6. 6 Schneider M, Hoepelman A, Schattenkerk J, Nielsen T, Van der Graaf Y, Frissen J et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection, N Engl J Med 1992 ; 26 : 1836-41
7. 7 Hardy W, Feinberg J, Finkelstein D, Power M, He W, Haczka C et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992 ; 26 : 1842-8
8. 8 Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med 1992 ;26 : 1853-60
9. 9 Ruskin J, Remington JS. Toxoplasmosis in the immunocompromised host. Ann Intern Med 1976 ; 84 : 193-202
10. 10 Casassus P, Padrazzi B, Lhote F, Jarousse B. Prévention des infections parasitaires. Presse Méd 1997 ; 26 : 334-9
11. 11 Direction Générale de la Santé. Surveillance du sida en France. Bull Épidémiol Hebdo 1995 ; 22 : 97-104
12. 12 Renold C, Sugar A, Chave JP, Perrin L, Delavelle J, Pizzolato G et al. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine 1992 ; 71 : 224-39
13. 13 Raffi F, Aboulker JP, Michelet C, Reliquet V, Pelloux H, Huart A et al. A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. AIDS 1997 ; 11 : 177-84
14. 14 Oksenhendler E, Charreau I, Tournerie C, Azihary M, Carbon C, Aboulker JP. Toxoplasma gondii in advanced HIV infection. AIDS 1994 ; 8 : 483-7
15. 15 Richard FO, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995 ; 21 : 49-56
16. 16 Leport C, Chêne G, Morlat P, Luft B, Rousseau F, Pueyo S et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. J Infect Dis 1996 ; 173 : 91-7
17. 17 Van Delden C, Gabriel V, Sudre P, Flepp M, Von Overbeck J, Hirschel B. Reasons for failure of prevention of Toxoplasma encephalitis. AIDS 1996 ; 10 : 509-13
18. 18 Raviglione MC, Nash EN, Cortes H, Mariuz P, Sanjana V. Intermittent cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia. Lancet 1990 ; 1 : 180
19. 19 Carr A, Tindall B, Penny R, Cooper DA. Trimethoprim-sulfamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992 ; 6 : 165-71
20. 20 Ruskin J, Lariviere M. Low-dose cotrimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991 ; 337 : 468-71
21. 21 O'Farrell N, Bradbeer C, Fitt S, Welch JM, Bateman NT. Cerebral toxoplasmosis and cotrimoxazole prophylaxis. Lancet 1991 ; 337 : 986
22. 22 Zangerle R, Allerberger F. Effect of prophylaxis against Pneumocystis carinii on toxoplasma encephalitis. Lancet 1991 ; 337 : 1232
23. 23 Nicholas P, Pierone G, Lin J, Gertman A, Schechter C, Masci J. Trimethoprim-sulfamethoxazole in the prevention of cerebral toxoplasmosis [abstract]. International Conference on AIDS, San Francisco, June 20-24, 1990
24. 24 Carr A, Tindall B, Brew BJ, Marriot D, Harkness J, Penny R et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992 ; 117 : 106-11
25. 25 Antinori A, Murri R, Ammassari A, De Luca A, Linzalone A, Cingolani A et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995 ; 9 : 1343-50
26. 26 Caurnes E, Lheritaux F, Gentilini M. Cotrimoxazole prophylaxis for toxoplasmosis. Ann Intern Med 1993 ; 118 : 395
27. 27 Dannemann B, McCutchan JA, Israelski D, Antoniskis D, Leport C, Luft B et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992 ; 116 : 33-43
28. 28 Wanke C, Tuazon CU, Kovacs A, Dina T, Davis D, Barton N et al. Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy. Am J Trop Med Hyg 1987 ; 36 : 509-16
29. 29 Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combinaison in 35 patients with the acquired immunodeficiency syndrome: efficacy of long-term continuous therapy. Am J Med 1988 ; 84 : 94-100
30. 30 Katlama C, De Wit S, O'Doherty E, Van Glabeke, Clumeck N. Pyrimethamine-clindamycin vs pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996 ; 22 : 268-75
31. 31 Katlama C, Mouthon B, Gourdon D, Lapierre D, Rousseau F. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. AIDS 1996 ; 10 : 1107-12